Assignee
PHARVARIS GMBH
CH·2 granted patents·6 pending applications·0 citations·filing 2020–2023
Top patents by PatentIndex Score
8 records- 0157US2025228782A1Solid extended-release composition comprising bradykinin b2-receptor antagonistsPHARVARIS GMBH·Filed 2023·Application pending·0 cites
- 0257US2025228781A1Solid composition comprising solubilised bradykinin b2-receptor antagonistsPHARVARIS GMBH·Filed 2023·Application pending·0 cites
- 0355US2025268887A1Therapeutic uses of bradykinin b2-receptor antagonistsPHARVARIS GMBH·Filed 2023·Application pending·0 cites
- 0454US2024350418A1Lipid-based composition for oral administration of bradykinin b2-receptor antagonistsPHARVARIS GMBH·Filed 2022·Application pending·0 cites
- 0554US2025145584A1Solid form of a bradykinin b2-receptor antagonistPHARVARIS GMBH·Filed 2022·Application pending·0 cites
- 0649US2023338358A1Prophylaxis and treatment of angioedemaPHARVARIS GMBH·Filed 2021·Application pending·0 cites
- 0741US12391681B2(R)-3-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)morpholine derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseasesPHARVARIS GMBH·Filed 2020·Granted Aug 19, 2025·0 cites·14 claims
- 0841US12312330B21-((S)-1-(3-chloro-5-fluoro-2-((4-(1h-pyrazol-1-yl)-2-methylquinolin-8-yloxy)methyl)phenyl)ethyl)-imidazolidine-2,4-dione derivatives and related compounds as bradykinin (BK) B2 receptor antagonist for treating skin diseasesPHARVARIS GMBH·Filed 2020·Granted May 27, 2025·0 cites·12 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →